B型肝炎検査市場：市場規模（セグメント別）、シェア、規制、償還、予測（～2033年）

B型肝炎は世界中で肝臓疾患の一般的な原因であり、1982年以来有効なワクチンが利用できるようになったにもかかわらず、ほとんどの政府にとって依然として大きな問題です。世界保健機関（WHO）は、すべての乳幼児にB型肝炎の予防接種を受けることを推奨しており、現在では世界各国で普遍的な予防接種が実施されています。妊婦のHBVスクリーニングは、ほとんどの国で標準的な治療法であり、赤ちゃんへの感染リスクを減らすための費用対効果の高い戦略であると考えられています。通常、妊婦は妊娠初期にスクリーニングを受けます。HBVに感染するリスクが高い妊婦については、妊娠第3期の初め（28週）または分娩時に検査を繰り返すこともあります。

B型肝炎ウイルス検査には、B型肝炎酵素免疫測定/酵素結合免疫吸着測定（EIA/ELISA）検査、B型肝炎核酸増幅検査（NAAT）、マルチパラメーターHIV、B型肝炎、C型肝炎NAATが含まれます。

当レポートは、世界のB型肝炎検査市場について詳細に考察し、市場における競合情勢、SWOT分析、2033年までの市場予測、COVID-19の影響、地域、国別の動向などを提供しています。

目次

現在上市されているB型肝炎検査と競合情勢

• 主要な業界動向の洞察
• B型肝炎検査のセグメント別総市場収益と2015年～2033年の市場展望
• 個数、平均販売価格、市場価値に関する詳細データ

世界、地域、国別の洞察

• B型肝炎検査市場のSWOT分析
• B型肝炎検査市場に関する競合力学の洞察と動向
• 国別の医療制度の概要
• 国別の償還政策
• 国別の医療技術に関する規制の状況

List of Tables

Not Applicable

List of Figures

Not Applicable

Abstract

Hepatitis B Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.

The model discusses in detail the impact of COVID-19 on Hepatitis B Tests market for the year 2020 and beyond. Hepatitis B is a common cause of liver disease across the globe, and remains a major issue for most of the governments despite the fact that an effective vaccine has been available since 1982. The World Health Organization (WHO) recommends that all infants receive the hepatitis B vaccination and universal vaccinations have now been implemented in numerous countries worldwide. Screening of pregnant women for HBV is standard of care in most countries and considered to be a cost-effective strategy for reducing the risk of transmission to the baby. Women are typically screened during their first trimester of pregnancy. For pregnant women at high-risk of acquiring HBV, testing is sometimes repeated at the beginning of the third trimester (28 weeks) or at the time of delivery.

HBV tests are performed for a number of purposes:

i) screening of suspected infection patients and diagnosis;

ii) monitoring of HBV-positive patients;

iii) screening or pregnant women; and

iv) screening of donors of human cells, tissues, and cellular and tissue-based products (HCT/P).

The Hepatitis B Virus Tests includes Hepatitis B Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) Tests, Hepatitis B Nucleic Acid Amplification Tests (NAATs) and Multi-parameter HIV, Hepatitis B, and Hepatitis C NAATs.

Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are:

Currently marketed Hepatitis B Tests and evolving competitive landscape:

• Insightful review of the key industry trends.
• Annualized total Hepatitis B Tests market revenue by segment and market outlooks from 2015-2033.
• Market level data on units, average selling prices and market values.

Global, Regional and Country level market specific insights:

• Qualitative market specific information is available with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country specific insights on the market.
• SWOT analysis for Hepatitis B Tests market.
• Competitive dynamics insights and trends provided for Hepatitis B Tests market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

• Country specific overview of the healthcare system.
• Country specific reimbursement policies.
• Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: Abbott Laboratories, Bio-Rad Laboratories Inc, Hologic Inc, Quidelortho Corp, Oswaldo Cruz Foundation, Grifols SA, F. Hoffmann-La Roche Ltd, Siemens AG, Qiagen NV, bioMerieux SA, DiaSorin SpA, and others.

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.

Scope

This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -

• CMO executives who must have deep understanding of the Hepatitis B Tests market place to make strategic planning and investment decisions.
• Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
• Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to -

• Understand the impact of COVID-19 on Hepatitis B Tests market.
• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving Hepatitis B Tests market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Hepatitis B Tests market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
• Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
• Track device sales in the global and country-specific Hepatitis B Tests market from 2015-2033.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

Not Applicable